294 related articles for article (PubMed ID: 31788992)
1. Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study.
Xiao Y; Cheng H; Wang L; Yu X
J Gynecol Oncol; 2020 Jan; 31(1):e2. PubMed ID: 31788992
[TBL] [Abstract][Full Text] [Related]
2. Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study.
Xia X; Jiang W; Qi W; Hong B; Zhao W
Oncol Res Treat; 2020; 43(12):649-655. PubMed ID: 33045704
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients.
Zhang L; Chen L; Yu H
Invest New Drugs; 2020 Aug; 38(4):1186-1191. PubMed ID: 31637668
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study.
Yang H; Chen M; Mei Z; Xie C; Zhou Y; Qiu H
Cancer Med; 2021 Jul; 10(13):4282-4290. PubMed ID: 33987959
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy.
Yang H; Sun S; Mei Z; Xiang Q; Yang C; Chen M; Xie C; Zhou Y; Qiu H
Drug Des Devel Ther; 2021; 15():4665-4674. PubMed ID: 34815663
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study.
Yu J; Xu Z; Li A; Zhang J; Wang Y; Zhao H; Zhu H
Drug Des Devel Ther; 2019; 13():3419-3424. PubMed ID: 31576114
[TBL] [Abstract][Full Text] [Related]
7. Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases.
Xu J; Liu X; Yang S; Shi Y
Oncol Res; 2020 Mar; 28(2):127-133. PubMed ID: 31610827
[TBL] [Abstract][Full Text] [Related]
8. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
Lan C; Shen J; Wang Y; Li J; Liu Z; He M; Cao X; Ling J; Huang J; Zheng M; Zou G; Yan H; Liu Q; Yang F; Wei W; Deng Y; Xiong Y; Huang X
J Clin Oncol; 2020 Dec; 38(34):4095-4106. PubMed ID: 33052760
[TBL] [Abstract][Full Text] [Related]
9. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
[TBL] [Abstract][Full Text] [Related]
10. Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study.
Li H; Zeng J; Jin X; Yu X; Zhou G; Hong W
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1083-1090. PubMed ID: 30937519
[TBL] [Abstract][Full Text] [Related]
11. Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study.
Guo Q; Sun Y; Kong E; Rao L; Chen J; Wu Q; Zhang T; Liu N; Li M; Sun L
Medicine (Baltimore); 2020 Mar; 99(11):e19372. PubMed ID: 32176061
[TBL] [Abstract][Full Text] [Related]
12. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
Ruan X; Liang JH; Pan Y; Cai R; Zhang RJ; He Z; Yang X; Niu Z; Jiang W
Cancer; 2021 Sep; 127(17):3163-3171. PubMed ID: 34043812
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
[TBL] [Abstract][Full Text] [Related]
15. Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma.
Zeng DX; Lei W; Wang CG; Huang JA; Jiang JH
Cancer Chemother Pharmacol; 2019 Mar; 83(3):439-442. PubMed ID: 30547193
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study.
Nie C; Lv H; Xing Y; Chen B; Xu W; Wang J; Chen X
BMC Cancer; 2021 Feb; 21(1):189. PubMed ID: 33622272
[TBL] [Abstract][Full Text] [Related]
17. Apatinib as an optional treatment in metastatic colorectal cancer.
Li A; Wang K; Xu A; Wang G; Miao Y; Sun Z; Zhang J
Medicine (Baltimore); 2019 Aug; 98(35):e16919. PubMed ID: 31464927
[TBL] [Abstract][Full Text] [Related]
18. A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.
Chen X; Qiu T; Zhu Y; Sun J; Li P; Wang B; Lin P; Cai X; Han X; Zhao F; Shu Y; Chang L; Jiang H; Gu Y
Oncologist; 2019 Jul; 24(7):883-e407. PubMed ID: 30877190
[TBL] [Abstract][Full Text] [Related]
19. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
Oaknin A; Friedman CF; Roman LD; D'Souza A; Brana I; Bidard FC; Goldman J; Alvarez EA; Boni V; ElNaggar AC; Passalacqua R; Do KTM; Santin AD; Keyvanjah K; Xu F; Eli LD; Lalani AS; Bryce RP; Hyman DM; Meric-Bernstam F; Solit DB; Monk BJ
Gynecol Oncol; 2020 Oct; 159(1):150-156. PubMed ID: 32723675
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study.
Liu Z; Zheng Z; Dong L; Guo X; Jia X; Wang J; Meng L; Cui X; Jiang X
Sci Rep; 2022 Oct; 12(1):18327. PubMed ID: 36316341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
